GNA Biosolutions announces leadership changes following Series C closing

GNA closed the financing round with over 13.5 million US dollars


Dr. Federico Buersgens, CEO, co-founder, Dr. Anastasia Liapis, Vice President Strategic Marketing & Partnerships, Dr. Lars Ullerich, CBO, co-founder, Dr. Joachim Stehr, CSO, co-founder, GNA Biosolutions (v.l.n.r.)

GNA Biosolutions, a developer of ultrafast molecular diagnostics platforms, announced  leadership changes in conjunction with its plans to develop a Point of Care human diagnostics system, for which the company secured funding amounting to 13.5 million US dollars in 2019.

“As we continue our efforts to bring our POC platform to the market, we are focused on ensuring that we have the right team and organizational structure in place. GNA’s realignment of key leadership roles is intended to streamline our organizational structure for the next phase in our trajectory,” said co-founder and newly appointed Chief Executive Officer (CEO), Federico Buersgens.

© GNA Biosolutions

Further changes to GNA’s leadership team comprise co-founder Dr. Lars Ullerich assuming responsibilities of Chief Business Officer (CBO) and co-founder Dr. Joachim Stehr assuming the duties of Chief Scientific Officer (CSO). Dr. Anastasia Liapis, who supported fundraising of GNA’s 13.5 million US dollar Series C financing round, has been ­promoted to VP to oversee Strategic Marketing & ­Partnerships.

“We remain focused on our core technology development expertise, while further developing GNA’s product pipeline. We are committed to delivering products for healthcare providers and the patients they serve.” said Mr. Buersgens.
The company’s POC platform will ­diagnose ­infectious diseases near the patient in just a few minutes, instead of traditional methods which can take hours.